Enhertu plus precise radiation for HER2+ breast cancer brain tumors
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests a combination of a targeted drug (Enhertu) with precise radiation (SRS) for people whose HER2-positive breast cancer has spread to the brain. It aims to see if this combo is safe and effective for treating brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HER2-positive breast cancer that has spread to your brain (newly diagnosed).
- You can have 1 to 10 brain tumors, each 3 cm (about 1.2 inches) or smaller.
- You should be able to do most daily activities (ECOG score 0, 1, or 2).
- You must not have had prior treatment with Enhertu (trastuzumab deruxtecan) or prior radiation to the brain.
- Your heart, liver, kidney, and blood cell counts must be in good enough shape (check with your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
This trial tests whether adding radiation therapy to a targeted cancer drug (trastuzumab rezetecan) is better than the drug alone for women with HER2-positive breast cancer that has spread to the brain. If you have untreated brain tumors from this type of breast cancer, this study aims to find the best way to stop them from growing.
This trial tests a combination of a targeted drug (T-DXd) and precise radiation (stereotactic radiotherapy) for people with HER2-positive breast cancer that has spread to the brain. The goal is to see if this approach can better control brain tumors.
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
This trial tests whether adding neratinib to T-DXd (trastuzumab deruxtecan) works better than T-DXd alone for women with HER2-positive breast cancer that has spread to the brain. It is for those who have not had these specific drugs before.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.